#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Kaposi's sarcoma Hypophosphatasia Cholestatic pruritus Amyotrophic lateral sclerosis gene carrier Pouchitis Uterine leiomyosarcoma Pleural mesothelioma malignant Drug eruption Exudative retinopathy Anal fistula Adrenogenital syndrome Asthma Medullary thyroid cancer Dementia IPEX syndrome More trials…

    Learn about Rare Diseases

    Waldenstrom’s macroglobulinaemia refractory Pemphigoid – Trials in Disease Piriformis syndrome Anaplastic thyroid cancer Osteosarcoma metastatic – Trials in Disease Testicular leiomyosarcoma Advanced systemic mastocytosis – Treatment Activated PI3 kinase delta syndrome Bronchiolitis obliterans syndrome – Trials in Disease Hereditary neuropathic amyloidosis – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    R-Azasetron Besilate Timrepigene Emparvovec Cefixime VINBLASTINE Bay 2927088 T89 Olive Oil, Refined Norepinephrine Retinol Palmitate Tiragolumab Posenacaftor APROTININ Upacicalcet Sodium Hydrate Alitretinoin Vedolizumab PRILOCAINE HYDROCHLORIDE HUMAN THROMBIN Pegenzileukin Lonapegsomatropin [11C]Az14193391 More therapies…

    Learn about Your Condition

    Skin candida Thrombocytopenia Lung adenocarcinoma stage III Compulsive sexual behaviour Ovarian cancer metastatic Nephropathy Vestibular disorder Neurotrophic keratopathy Cluster headache Anaemia Biliary tract operation Intracranial calcification Antisynthetase syndrome Chronic kidney disease Juvenile spondyloarthritis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Oscar Lambret

Centre Oscar Lambret

3 Rue Frederic Combemale, Lille, 59000, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Dostarlimab
    • Niraparib Tosilate Monohydrate
    Belgium Czechia Denmark Finland France Germany +7

  • Study on Chemotherapy with Cisplatin, Fluorouracil, and Docetaxel for Patients with Locally Advanced Squamous Cell Carcinoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Metastatic squamous cell carcinoma
    Investigated Drugs:
    • Cisplatin
    • Docetaxel
    • Fluorouracil
    France

  • Durvalumab Maintenance Therapy for Frail Patients with Limited Stage Small Cell Lung Cancer After Chemoradiotherapy

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Durvalumab
    France

  • Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Pertuzumab
    • Trastuzumab
    • Tucatinib
    Austria Belgium Czechia Finland France Germany +6

  • Study of Niraparib and Dostarlimab for Children with Recurrent or Hard-to-Treat Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Neoplasm
    • Neoplasm malignant
    Investigated Drugs:
    • Dostarlimab
    • Niraparib Tosilate Monohydrate
    Czechia France Germany Hungary Spain

  • Study of Pembrolizumab with Chemotherapy for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Adenocarcinoma gastric
    • Oesophageal adenocarcinoma
    Investigated Drugs:
    • Capecitabine
    • Cisplatin
    • Fluorouracil
    Czechia Denmark France Germany Ireland Italy +2

  • Study on the Safety and Effectiveness of MK-1200 for Patients with Advanced Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Mk-1200
    France Italy Poland Spain

  • Study on the Effects of Ezabenlimab and BI 907828 in Adult Patients with Advanced or Metastatic Solid Tumors

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • (3S,3’S,3A’s,10A’s)-6-Chloro-3′-(3-Chloro-2-Fluorophenyl)-1′-(Cyclopropylmethyl)-6′-Methyl-2-Oxo-1,2,3′,3A’,10′,10A’-Hexahydro-1’H-Spiro[Indole-3,2′-Pyrrolo[2′,3′:4,5]Pyrrolo[1,2-B]Indazole]-7′-Carboxylic Acid
    • Ezabenlimab
    France

  • Study on Setanaxib and Pembrolizumab for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Pembrolizumab
    • Setanaxib
    France Italy Poland Spain

  • Study on TTX-030, Budigalimab, and Chemotherapy for Untreated Metastatic Pancreatic Cancer Patients

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Pancreatic carcinoma metastatic
    Investigated Drugs:
    • Budigalimab
    • Gemcitabine Hydrochloride
    • Paclitaxel
    Czechia France Italy Spain
Previous Page
1 … 20 21 22 23 24 … 26
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!